When the COVID-19 pandemic began, no industry was hit more drastically than the healthcare industry. Experts and organizations across the industry had to manage both the enormous volume of COVID patients, while also having to make sure patients with other medical issues could be treated and monitored in a socially distant fashion. As the pandemic continued, the adoption of telehealth by the industry quickly became the solution healthcare experts were looking for, leading to an increased use of devices that specialize in remote patient monitoring that allow patients and physicians to be more connected than ever.
Author: Praveen Suthrum
In the past year, nearly 5,000 clinical trials were launched to test life-saving treatments and vaccines for the novel coronavirus. Covid-19 clinical trial enrollment is 80% higher than average. However, this is less impressive when considering that for many diseases, such as cancer, less than 10% of eligible patients enroll in a trial. Patients often only enroll in a drug trial when existing forms of treatments have already failed. On top of that, not all diagnosed patients are eligible for trial participation — determining eligibility alone can be a herculean task. For those that are eligible, participating in a trial is often a cost- and time-intensive…
Patients with Crohn’s disease who were biologic naive had similar rates of clinical remission and speed of onset whether they were treated with Remicade or Stelara, according to study results. “Rapidity of symptom relief has become a means by which biologics are differentiated,” Neeraj Narula, MD, from the division of gastroenterology at McMaster University, and colleagues wrote. “TNF alpha antagonists such as [Remicade (infliximab, Janssen)] are often perceived to be the more rapidly acting than biologics with newer mechanisms of action. However, published comparisons for rapidity of symptom relief are generally lacking in CD.”
A national survey of physicians elicits beliefs regarding how the Merit-based Incentive Payment System domains drive value. ABSTRACT Objectives: To understand physician perspectives about drivers of value within the 4 domains—quality, improvement activities, promoting interoperability, and cost—of the Merit-based Incentive Payment System (MIPS). Study Design: National web-based physician survey. Methods: Those surveyed who believed that MIPS domain activities would improve value were asked about mechanisms—quality (structural quality, process quality, or outcome quality), patient experience, and/or cost—they believe would drive those improvements. Results: Of 1431 physicians, 51% responded. Most believed that value would be improved by activities in the 4 MIPS domains of quality (55%),…
The diagnostic yield of pancreatic ductal adenocarcinoma was substantial in high-risk mutation carrier but non-existent in mutation-negative proven familial pancreatic cancer kindreds. “Nevertheless, timely identification of resectable lesions proved challenging despite the concurrent use of two imaging modalities, with [endoscopic ultrasonography (EUS)] outperforming [MRI/cholangiopancreatography (MRI/MRCP)],” Kasper A. Overbeek, MD, from the department of gastroenterology and hepatology and the Erasmus MC Cancer Institute, Erasmus University Medical Center in Rotterdam, the Netherlands, and colleagues wrote. “Overall, surveillance by imaging yields suboptimal results with a clear need for more sensitive diagnostic markers, including biomarkers.”
This document represents the official recommendations of the American Gastroenterological Association (AGA) and was developed by the AGA Clinical Guideline Committee and approved by the AGA Governing Board. Development of this guideline was fully funded by the AGA Institute with no additional outside funding. Obesity is a global pandemic, affecting about 40% of adults in the United States. There is a vast area of unmet need with respect to weight-loss interventions, as only 1.1% of eligible patients with obesity are receiving primary bariatric surgery. Endoscopic bariatric therapies have evolved as an attractive tool for weight loss; however, <5% of patients…
Artificial intelligence (AI) is rapidly becoming an essential tool in the medical field as well as in daily life. Recent developments in deep learning, a subfield of AI, have brought remarkable advances in image recognition, which facilitates improvement in the early detection of cancer by endoscopy, ultrasonography, and computed tomography. In addition, AI-assisted big data analysis represents a great step forward for precision medicine. This review provides an overview of AI technology, particularly for gastroenterology, hepatology, and pancreatology, to help clinicians utilize AI in the near future.
Wision AI, a leader in developing computer-aided diagnostic algorithms and real-time systems to improve the accuracy and effectiveness of diagnostic imaging, today announced the publication of data demonstrating positive results and competitive advantages of using its artificial intelligence computer-aided polyp detection (CADe) system during colorectal cancer screening in a U.S. patient population. In this world’s first external independent randomized controlled trial (RCT) of AI in the medical field conducted in the United States (NCT03925337), 232 patients were enrolled for screening and surveillance colonoscopy in four leading U.S. academic institutions. Results indicated that the Wision AI‘s CADe device, EndoScreener, significantly reduced…
A Subsequent International Survey of 121 Centers From 35 Countries.
CMS released several final payment rules for fiscal year 2022 that will take effect Oct. 1. Below is a breakdown of 21 things to know about the final rules: Inpatient facilities